<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01098877</url>
  </required_header>
  <id_info>
    <org_study_id>B1261002</org_study_id>
    <nct_id>NCT01098877</nct_id>
  </id_info>
  <brief_title>First In Human Study Of Increasing Oral Doses Of PF-04634817</brief_title>
  <official_title>A Double Blind, Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Pharmacokinetics (In The Fed And Fasted State), Safety And Toleration Of Single Oral Doses Of PF-04634817 In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the hypothesis that at doses and plasma concentrations which affect
      pharmacodynamic markers of activity at the chemokine receptors, CCR2 and CCR5, the compound
      is safe and well tolerated. It will also evaluate the hypothesis that the pharmacokinetic
      profile is robust and consistent with a once or twice a day therapeutic administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and toleration: adverse events, supine and standing vital sign measurements, telemetry, 12-lead ECGs, blood and urine tests</measure>
    <time_frame>0-3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics: Cmax, Tmax, AUClast, AUCinf, AUC0-24, CL/F, Vz/F and T1/2</measure>
    <time_frame>0-4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary pharmacokinetics: Aet (mount excreted in urine), Aet% and CLr</measure>
    <time_frame>0-2 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>p-ERK inhibition in human monocytes</measure>
    <time_frame>0-3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in circulating monocytes</measure>
    <time_frame>0-3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma MCP-1</measure>
    <time_frame>0-3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MIP 1B stimulated CCR5 receptor internalization</measure>
    <time_frame>0-3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MCP-1 stimulated CCR5 receptor internalization</measure>
    <time_frame>0-3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, 3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3, 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3, 900mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3, up to 900mg (fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3, placebo (fed)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817 Placebo</intervention_name>
    <description>Oral solution, placebo, single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817</intervention_name>
    <description>Oral solution, 1mg, single dose</description>
    <arm_group_label>Cohort 1, 1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817</intervention_name>
    <description>Oral solution, 3mg, single dose</description>
    <arm_group_label>Cohort 1, 3mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817</intervention_name>
    <description>Oral solution, 10mg, single dose</description>
    <arm_group_label>Cohort 1, 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817</intervention_name>
    <description>Oral solution, 30mg, single dose</description>
    <arm_group_label>Cohort 2, 30mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817</intervention_name>
    <description>Oral solution, 100mg, single dose</description>
    <arm_group_label>Cohort 2, 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817</intervention_name>
    <description>Oral solution, 300mg, single dose</description>
    <arm_group_label>Cohort 2, 300mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817</intervention_name>
    <description>Oral solution, 600mg, single dose</description>
    <arm_group_label>Cohort 3, 600mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817</intervention_name>
    <description>Oral solution, 900mg, single dose</description>
    <arm_group_label>Cohort 3, 900mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817</intervention_name>
    <description>Oral solution, up to 900mg, single dose after food</description>
    <arm_group_label>Cohort 3, up to 900mg (fed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04634817 Placebo</intervention_name>
    <description>Oral solution, placebo, single dose after food</description>
    <arm_group_label>Cohort 3, placebo (fed)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female (of non-child bearing potential) subjects between 18 and 55
             years of age.

          -  Body mass index of 17.5 to 30.5 kg/m2 and total body weight &gt; 50kg.

        Exclusion Criteria:

          -  Evidence or history of any clinically significant disease.

          -  Treatment with an investigational drug within 30 days of study start

          -  Use of prescription and non-prescription medicines within 7 days of study start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1261002&amp;StudyName=First%20In%20Human%20Study%20Of%20Increasing%20Oral%20Doses%20Of%20PF-04634817</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2010</study_first_submitted>
  <study_first_submitted_qc>April 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2010</study_first_posted>
  <last_update_submitted>October 12, 2010</last_update_submitted>
  <last_update_submitted_qc>October 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Phase1</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>toleration</keyword>
  <keyword>pharmacodynamics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

